AG0037GN

606143-52-6 | 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide

Chemical structure of 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide, CAS 606143-52-6
AG0037GN
sdsSDS
sdsCOA
TIP This product is typically in stock.Please contact us for quotation.
Request For Quotation

CAS Number 606143-52-6
Catalog Number AG0037GN(AGN-PC-0MZ8H6)
Chemical Name 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
IUPAC Name 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
InChI InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChI Key CYOHGALHFOKKQC-UHFFFAOYSA-N
MDL Number MFCD11977472
Molecular Formula C17H15BrClFN4O3
Molecular Weight 457.6814
NSC Number 741078
SMILES OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F
UNII 6UH91I579U
Synonyms
ARRY 142886, ARRY-142886, ARRY142886, AZD 6244, AZD-6244, AZD6244, selumetinib, Selumetinib, 606143-52-6, AZD6244, AZD 6244, ARRY-142886, AZD-6244, 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE, ARRY 142886, AZD6244 (Selumetinib), ARRY-886, Selumetinib (AZD6244), UNII-6UH91I579U, AZD6244(Selumetinib), 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide, CHEMBL1614701, CHEBI:90227, 6UH91I579U, NCGC00189073-01, NCGC00189073-02, AK-40782, C17H15BrClFN4O3, DSSTox_CID_28870, DSSTox_RID_83139, DSSTox_GSID_48944, 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-, Q-101405, AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, CAS-606143-52-6, ARRY142886, Selumetinib [USAN:INN], selumetinibum, 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-, PubChem21092, AZD 6244 Selumetinib, Selumetinib (USAN/INN), AZD-6244(Selumetinib), AZD6244 - Selumetinib, AZD 6244 (Selumetinib), JSPY-st000254, SCHEMBL155456, GTPL5665, QCR-91, Selumetinib, ARRY-142886, DTXSID3048944, CTK8B4577, EX-A020, SYN1016, CYOHGALHFOKKQC-UHFFFAOYSA-N, BCPP000367, CC-49, HMS3244G03, HMS3244G04, HMS3244H03, HMS3265K01, HMS3265K02, HMS3265L01, HMS3265L02, HMS3654O03, NSC 741O78, AOB87732, API01002, BCP01739, Tox21_113362, ABP000918, ANW-45526, BDBM50355497, MFCD11977472, NSC741078, RS0061, s1008, ZINC31773258, ARRY142886/AZD6244, AKOS015904255, Tox21_113362_1, ACN-031539, AN-4474, BCP9000354, CS-0059, DB11689, EX-8621, NSC-741078, SB14707, KS-0000003K, NCGC00189073-07, 4CA-0236, AC-25059, AJ-84328, AM808016, AZD6244,Selumetinib, ARRY-142886, BC004624, BC660025, CJ-17817, HY-50706, SC-85661, AZD6244 (Selumetinib ARRY-142886), AZD6244 (Selumetinib, ARRY142886), AB0007973, AX8165426, TX-013341, FT-0674552, ST24031611, SW202561-3, X2640, D09666, S-7764, 143A526, BRD-K57080016-001-01-9, I14-17010, 3EW, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide, 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxami, 6-(4-bromo-2-chloro-anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide, 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide, 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide, 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide, 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide, 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide, 6-(4-bromo-2-chlorophenylamino)-N-(2-hydroxyethoxy)-3,7-dimethyl-3H-benzo[d]imidazole-5-carboxamide, 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, MEK inhibitors, D0T5DP, D0TH0Z, CID10127622, A8207, A8446, A10257, C517975, Selumetinib, 99%, a highly selective MEK1 inhibitor - 1G 1g, ARRY-142886, Selumetinib, AZD-6244, ARRY142886, AZD6244, 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide,

Related Research Chemicals

CERTIFICATE OF ANALYSIS
Chemical Name: Batch Number:
Chemical Structure: CAS Registry No:
Product ID:
Manufacture Date:
Storage Temperature:
Formula:
Molecular Weight:
Quantity:
Analysis Data:
Test: Result:
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited